Bluebird Bio Raises $60M Series D Round To Treat Rare Diseases
This article was originally published in The Pink Sheet Daily
The gene therapy start-up taps diversified public and private investors, as well as strategic backer Shire, for one of the year’s biggest rounds of private capital funding for a biotech thus far.
You may also be interested in...
On the strength of interim Phase I/II data presented at ASH and an investor presentation Dec. 10, bluebird bio is enjoying substantial growth in its stock price for the week.
Two patients achieve independence from transfusions and show normalizing levels of hemoglobin in Phase II trial of experimental viral vector-based gene therapy. Bluebird’s share price soared on the promising news.
Despite pricing well below its range and trading down, Ambit could raise $90 million in an IPO and a private placement with existing investors. Also this week, gene therapy company bluebird bio filed for an IPO, and hematology play Portola made the rounds on its investor road show.